Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US-9492442-B2 · Nov 15, 2016 · US
Liposomes Useful for Drug Delivery
US2016338956A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016338956-A1 |
| Application number | US-201615227631-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 3, 2016 |
| Priority date | May 3, 2004 |
| Publication date | Nov 24, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1 . A pharmaceutical composition comprising irinotecan sucrose octasulfate precipitated in a matrix comprising one or more phospholipids, wherein the matrix has a size of approximately 110 nm and comprises a total of 500-550 mg irinotecan base per mmol of total phospholipids. 2 . The liposome composition of claim 1 , wherein the matrix comprises DSPC and cholesterol. 3 . The liposome composition of claim 2 , wherein the matrix comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 4 . The liposome composition of claim 1 , wherein the matrix comprises a total of 500 mg irinotecan base per mmol of total DSPC and PEG-DSPE. 5 . The liposome composition of claim 4 , wherein the matrix comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 6 . The liposome composition of claim 1 , wherein the matrix comprises a PEGylated lipid. 7 . A pharmaceutical composition comprising irinotecan sucrose octasulfate within a matrix comprising one or more phospholipids and having a size of approximately 110 nm, wherein the composition comprises a total of 500-550 mg irinotecan base per mmol of total phospholipids in the matrix, wherein at least 90% of the irinotecan in the pharmaceutical composition is in the irinotecan sucrose octasulfate within the matrix. 8 . The liposome composition of claim 7 , wherein the matrix comprises a PEGylated lipid. 9 . The composition of claim 8 , wherein the irinotecan sucrose octasulfate is precipitated within the matrix from irinotecan hydrochloride and sucrose octasulfate triethylammonium. 10 . The composition of claim 9 , wherein the irinotecan sucrose octasulfate is precipitated within the matrix. 11 . The liposome composition of claim 10 , wherein the matrix comprises DSPC and cholesterol. 12 . The liposome composition of claim 11 , wherein the matrix comprises DSPC, cholesterol, and PEG-DSPE in a molar ratio of 3:2:0.015. 13 . The liposome composition of claim 11 , wherein the matrix comprises a total of 500 mg irinotecan base per mmol of total DSPC and PEG-DSPE. 14 . The liposome composition of claim 8 , wherein the PEGylated lipid is PEG-DSPE. 15 . The liposome composition of claim 7 , wherein the composition comprises a total of 500 mg irinotecan base per mmol of total DSPC and PEG-DSPE. 16 . A pharmaceutical composition comprising irinotecan sucrose octasulfate salt precipitated within a lipid matrix comprising DSPC, cholesterol, and PEG2000-DSPE and having a size of approximately 110-120 nm, wherein the composition comprises a total of 500 mg irinotecan base per mmol of total DSPC and PEG2000-DSPE in the matrix, and wherein at least 90% of the irinotecan in the pharmaceutical composition is in the irinotecan sucrose octasulfate within the matrix. 17 . The composition of claim 16 , wherein the matrix consists of DSPC, cholesterol, and PEG2000-DSPE in a molar ratio of 3:2:0.015. 18 . The composition of claim 16 , wherein the irinotecan sucrose octasulfate is precipitated as a salt in the matrix. 19 . The composition of claim 16 , wherein the irinotecan sucrose octasulfate is formed in the matrix from irinotecan hydrochloride and sucrose octasulfate triethylammonium. 20 . The composition of claim 17 , wherein the irinotecan sucrose octasulfate is precipitated within the matrix.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
Antivirals · CPC title
- A61K9/127Primary
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016338956A1 cover?
- The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/127. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Nov 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).